Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$52.68 USD
+0.02 (0.04%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $52.72 +0.04 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
CYTK 52.68 +0.02(0.04%)
Will CYTK be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CYTK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CYTK
Cytokinetics (CYTK) Q2 Loss Wider Than Expected, Pipeline in Focus
Cytokinetics (CYTK) Reports Q2 Loss, Lags Revenue Estimates
CYTK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?
Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday
Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates
Other News for CYTK
Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant Program
Cytokinetics Announces Upcoming Presentations at the HCMS Scientific Sessions and the HFSA Annual Scientific Meeting
Edgewise Therapeutics price target raised by $10 at Leerink, here's why
Insider Sale: EVP Research & Development Fady Malik Sells 7,300 Shares of Cytokinetics Inc ...
Cytokinetics Announces Data From Phase 1 Study of CK-4021586